Modal Therapeutics is a stealth-stage biotechnology company, dedicated to the discovery and development of innovative and targeted therapies for patients with wide ranges of serious and rare diseases. We focus on leveraging the biology within the Tgf-beta superfamily, pivotal in regulating diverse cellular processes and tissue remodeling, to tackle the root causes of diseases that lack effective treatments. We are steered by a team of accomplished experts in Tgf-beta biology, protein science, pharmacology, and translational medicine.